[Changes of plasminogen activator inhibitor (PAI-1) during estrogen replacement therapy].
BACKGROUND
The purpose of the present study was to determine changes of plasminogen activator inhibitor-1 (PAI-1) as biochemical cardiovascular risk factor during the use of different administration methods in the early estrogen replacement therapy.


RESULTS
In a 12-week prospective, randomized, interventional, cross-over trial, oestradiol was administered orally in a dose of 2 mg daily or transdermally in a dose of 0.05 mg daily. Forty-five healthy postmenopausal women were included into the study within 12 weeks after the hysterectomy and ovariectomy (surgical castration). Forty-one women completed the study and their data were analyzed. The average age was of 49 +/- 6 years. PAI-1 was determined by bioimmunoassay (Chromolyze PAI-1). The PAI-1 level decreased statistically significantly (p = 0.001) after the oral oestrogen therapy from 11.39 +/- 12.02 IU/l to 5.0 +/- 5.27 IU/l. Changes are also significant compared with non-significant changes after the transdermal therapy.


CONCLUSIONS
The oral therapy reduced statistically significantly PAI-1 levels compared with the transdermal method of administration. This change is beneficial from the view of cardiovascular risk.
Zizka
Z
Z
Gynekologicko-porodnická klinika 1. LF UK a VFN, Praha. zdenek.zizka@lf1.cuni.cz
Fait
T
T
Vrablík
M
M
D000279:Administration, Cutaneous; D000284:Administration, Oral; D018592:Cross-Over Studies; D004958:Estradiol / Q000008:administration & dosage; D015914:Estrogen Replacement Therapy; D005260:Female; D006801:Humans; D007044:Hysterectomy; D008594:Menopause, Premature; D008875:Middle Aged; D010052:Ovariectomy; D017395:Plasminogen Activator Inhibitor 1 / Q000097:blood*
D017395:Plasminogen Activator Inhibitor 1; D004958:Estradiol